The Effects of Coenzyme A on Serum Lipids in Patients With Hyperlipidemia

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the lipid lowering effects and clinical safety of a natural hypolipidemic compound, coenzyme A （CoA） capsule in Chinese patients with moderate dyslipidemia.

Clinical Trial Description

Hyperlipidemia plays important roles in the development and progression of atherosclerosis. Modulating lipid levels has been shown to reduce the development of atherosclerosis and incidence of cardiovascular disease. The HMG-CoA reductase inhibitors (also known as statins) are the most effective agents available in the management of hyperlipidemia and prevention of major cardiovascular events. Although statin based therapy is commonplace in primary and secondary prevention, several economical, clinical and safety issues have been raised, so that there is ongoing research into new, safer and more effective agents to be used alone or in combination with existing cardiovascular drugs.

Coenzyme A (CoA) is a ubiquitous essential cofactor that plays a central role in the metabolism of carboxylic acids, including short- and long-chain fatty acids, as well as carbohydrate and protein. In the metabolic pathway of lipid, CoA participates in fatty acid β-oxidation, promoting triglyceride (TG) catabolism. Previous research revealed that insufficiency of CoA in vivo influenced fatty acid β-oxidation catabolism and impaired clearance of TG from plasma, which was supposed to be one plausible reason resulting in type Ⅱb and Ⅳ hyperlipoproteinemia. In addition, epidemiological studies showed the prevalence of serum lipids level increased with age, which may be related to the reduction of CoA synthesis in aging individuals. Moreover, studies on animals have given evidence to prove that supplement of CoA had normalizing activity on plasma lipids in dyslipidemia.

Pantethine is a versatile and very well tolerated hypolipidemic agent that can decrease serum triglycerides, LDL cholesterol, and apolipoprotein B, while increasing HDL cholesterol and apolipoprotein A-I. Pantethine is the disulfide of pantetheine which per se occurs naturally as a product of coenzyme A catabolism. Theoretically, antihyperlipidemia effect of CoA should be more directly and effectively than pantethine. Researches on rabbits and rats models prove that high dose CoA orally can relieve fasting hyperlipidemia and insulin resistance induced by high fat diet. So far there has not been sufficient clinical research data to support the efficacy of CoA in dyslipidemia patients. The present study shows, for the first time, the safety, effectiveness of oral CoA. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01645046
Study type	Interventional
Source	Zhejiang University
Contact
Status	Completed
Phase	Phase 2
Start date	October 2008
Completion date	August 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00000538` - Dietary Effects on Lipoproteins and Thrombogenic Activity	Phase 3
Completed	`NCT01146522` - Safety, Tolerability,Pharmacokinetics(PK)and Pharmacodynamics(PD)Assessment of LCQ908 in Patients With Severe Hypertriglyceridemia	Phase 1/Phase 2
Recruiting	`NCT01928342` - The Effects of Coenzyme A Combined With Statin on Serum Lipids in Patients With Hyperlipidemia	Phase 2/Phase 3
Terminated	`NCT01239992` - Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia	Phase 4
Completed	`NCT02933138` - Plasma Triglyceride Lipolysis in Multifactorial Chylomicronemia	N/A
Completed	`NCT01878227` - Comparison of Coenzyme A and Fenofibrate for Safety and Efficacy On Patients With Hyperlipidemia	Phase 3
Completed	`NCT01811082` - Comparison of Coenzyme A and Pantethine Capsule for Safety and Efficacy On Patients With Hyperlipidemia	Phase 3
Active, not recruiting	`NCT05256654` - A Study of LY3561774 in Participants With Mixed Dyslipidemia	Phase 2
Completed	`NCT00005128` - Lipid Research Clinics Population Studies	N/A
Completed	`NCT01057654` - A Study Comparing the Mechanisms of Action of Lifibrol and Pravastatin	Phase 3
Completed	`NCT00001226` - Lipoprotein Metabolism in Normal Volunteers and Patients With Abnormal Levels of Lipoproteins	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.